This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Delving into the Phase 3 ALIGN clinical trial of atrasentan in patients with IgA nephropathy.
Ticker(s): NVSWho's the expert?
Institution: Yale
- Clinical Professor of Medicine, Yale University & Section Chief of Nephrology at the Hospital of St. Raphael.
- Manages large CKD dialysis population treating many patients with iron deficiency (175 with CKD anemia-- 50 hemodialysis patients, 40 peritoneal dialysis patients and 85 CKD patients )
- Speaker at many international Nephrology conferences and has followed the Roxadustat data very closely.
Interview Goalto discuss the current standard of care and the potential of atrasentan, a therapy being developed by Novartis for the treatment of IgAN.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
